| 1 |
Sayah R, Awada S, Ismaiil L, Hatem G. Assessment of the differences between generic and biosimilar drugs: A brief literature review. Journal of Generic Medicines 2023. [DOI: 10.1177/17411343231157309] [Reference Citation Analysis]
|
| 2 |
Ismail S, Abu Esba L, Khan M, Al-Abdulkarim H, Modimagh H, Yousef C. An Institutional Guide for Formulary Decisions of Biosimilars. Hosp Pharm 2023;58:38-48. [PMID: 36644755 DOI: 10.1177/00185787221138007] [Reference Citation Analysis]
|
| 3 |
Leal I, Steeples LR, Wong SW, Giuffre C, Pockar S, Sharma V, Green EK, Payne J, Jones NP, Chieng ASE, Ashworth J. Update on the systemic management of non-infectious uveitis in children and adolescents. Surv Ophthalmol 2023:S0039-6257(23)00001-2. [PMID: 36682467 DOI: 10.1016/j.survophthal.2023.01.002] [Reference Citation Analysis]
|
| 4 |
Nabi H, Hendricks O, Jensen DV, Loft AG, Pedersen JK, Just SA, Danebod K, Munk HL, Kristensen S, Manilo N, Colic A, Linauskas A, Thygesen PH, Christensen LB, Kalisz MH, Lomborg N, Chrysidis S, Raun JL, Andersen M, Mehnert F, Krogh NS, Hetland ML, Glintborg B. Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry. RMD Open 2022;8:e002560. [DOI: 10.1136/rmdopen-2022-002560] [Reference Citation Analysis]
|
| 5 |
Allocati E, Godman B, Gobbi M, Garattini S, Banzi R. Switching Among Biosimilars: A Review of Clinical Evidence. Front Pharmacol 2022;13:917814. [DOI: 10.3389/fphar.2022.917814] [Reference Citation Analysis]
|
| 6 |
Cohen HP, Hachaichi S, Bodenmueller W, Kvien TK, Danese S, Blauvelt A. Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies. BioDrugs 2022. [PMID: 35881304 DOI: 10.1007/s40259-022-00546-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 7 |
Feijó Azevedo V, Moots R. Introductory Chapter: Biosimilars - A Regulatory and Clinical Perspective. Biosimilars 2022. [DOI: 10.5772/intechopen.104746] [Reference Citation Analysis]
|
| 8 |
Barbier L, Vulto AG. Interchangeability of Biosimilars: Overcoming the Final Hurdles. Drugs 2021;81:1897-903. [PMID: 34727332 DOI: 10.1007/s40265-021-01629-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
